Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-316,311 in Major Depressive Disorder
NCT00143091Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of CP-316,311 in major depressive disorder (MDD), sponsored by Pfizer. Started Apr 2005; status: terminated.
02
Drugs
CP-316,311
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00143091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143091.